Skip to content

RNTX RNTX Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$66.37B-11.5%
CTO
Citius Oncology, Inc.CTOR
$65.43M+17.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$25.03M-1.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$431.05M+1.3%
LQD
Liquidia CorporationLQDA
$292.95M+64.8%
United Therapeutics logo
United TherapeuticsUTHR
$813.1M-13.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's total liabilities?
RNTX (RNTX) reported total liabilities of $14.7M in Q1 2026.
How has RNTX's total liabilities changed year-over-year?
RNTX's total liabilities increased by 89.7% year-over-year, from $7.75M to $14.7M.
What is the long-term trend for RNTX's total liabilities?
Over 5 years (2020 to 2025), RNTX's total liabilities has grown at a 11.6% compound annual growth rate (CAGR), from $4.18M to $7.24M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.